This segment focuses on the development and commercialization of next-generation sequencing (NGS)-based diagnostic tests for cancer therapy selection. Burning Rock offers a comprehensive portfolio of tests applicable to various cancer types, including lung, gastrointestinal, prostate, and breast cancers. These tests utilize both tissue and liquid biopsy samples to identify actionable genomic alterations, enabling personalized treatment decisions. Research and development efforts are directed towards expanding the test menu, improving assay sensitivity and specificity, and incorporating novel biomarkers. The company collaborates with pharmaceutical partners to develop companion diagnostics for targeted therapies, enhancing patient access to precision medicine. Future opportunities include expanding into new geographic markets and developing multi-cancer early detection assays.

This segment is dedicated to the development and commercialization of companion diagnostics (CDx) in collaboration with pharmaceutical companies. Burning Rock leverages its NGS platform and expertise in cancer genomics to develop CDx assays that identify patients most likely to benefit from specific targeted therapies. These collaborations involve joint research and development activities, clinical trials, and regulatory submissions. The CDx assays are designed to guide treatment decisions, improve patient outcomes, and accelerate the adoption of precision medicine in oncology. Burning Rock's partnerships with leading pharmaceutical companies, such as AstraZeneca, Bayer, and Boehringer Ingelheim, demonstrate its commitment to advancing personalized cancer care. Future growth opportunities include expanding the CDx portfolio to cover a wider range of targeted therapies and cancer types.